- Home
- BBBY vs VSTM Comparison
BBBY vs VSTM Comparison
Compare BBBY & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BBBY | VSTM |
|---|---|---|
| Founded | 1971 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 573.5M | 581.6M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | BBBY | VSTM |
|---|---|---|
| Price | $6.08 | $10.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $8.00 | ★ $13.38 |
| AVG Volume (30 Days) | 1.8M | ★ 2.1M |
| Earning Date | 10-27-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,074,337,000.00 | $13,379,000.00 |
| Revenue This Year | N/A | $183.10 |
| Revenue Next Year | $5.03 | $271.39 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 33.79 |
| 52 Week Low | $3.54 | $3.46 |
| 52 Week High | $12.65 | $11.25 |
Technical Indicators
Market Signals| Indicator | BBBY | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 41.98 | 55.73 |
| Support Level | $5.68 | $9.95 |
| Resistance Level | $6.79 | $10.70 |
| Average True Range (ATR) | 0.39 | 0.56 |
| MACD | 0.14 | 0.02 |
| Stochastic Oscillator | 47.73 | 59.05 |
Price Performance
Historical ComparisonAbout BBBY Bed Bath & Beyond Inc.
Bed Bath & Beyond Inc is an ecommerce-focused retailer with an affinity model that owns or has ownership interests in various retail brands, offering a comprehensive array of products and services that enable its customers to enhance everyday life through quality, style, and value. The Company currently owns Bed Bath & Beyond, Overstock, buybuy BABY, and other related brands and websites as well as a blockchain asset portfolio.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.